



Consolidated Financial Statements

For the Years Ended December 31, 2016 and 2015

## Table of Contents

---

	Page
<b>Independent Auditor's Report</b>	1 - 2
<b>Consolidated Financial Statements:</b>	
Consolidated Statements of Financial Position	3
Consolidated Statements of Activities and Changes in Net Assets	4 - 5
Consolidated Statements of Functional Expenses	6 - 7
Consolidated Statements of Cash Flows	8
Notes to Consolidated Financial Statements	9 - 25

## **Independent Auditor's Report**

### **To the Board of Directors PATH**

We have audited the accompanying consolidated financial statements of PATH and Subsidiaries (collectively, the Organization) which comprise the consolidated statements of financial position as of December 31, 2016 and 2015, and the related consolidated statements of activities and changes in net assets, functional expenses and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### **Management's Responsibility for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



T: 425-454-4919  
T: 800-504-8747  
F: 425-454-4620

10900 NE 4th St  
Suite 1700  
Bellevue WA  
98004

[clarknuber.com](http://clarknuber.com)

## Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Organization as of December 31, 2016 and 2015, and the changes in its net assets and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

*Clark Nuber P.S.*

Certified Public Accountants

May 31, 2017

PATH AND SUBSIDIARIES

Consolidated Statements of Financial Position  
December 31, 2016 and 2015  
(In Thousands)

	<u>2016</u>	<u>2015</u>
<b>Assets</b>		
Cash and cash equivalents	\$ 103,682	\$ 118,096
Investments	181,697	198,894
Contributions and awards receivable, net	248,430	278,519
Prepaid expenses and other	6,699	8,523
Other receivables	1,092	871
Furniture, equipment and leasehold improvements, net	<u>13,626</u>	<u>15,530</u>
<b>Total Assets</b>	<b><u>\$ 555,226</u></b>	<b><u>\$ 620,433</u></b>
<b>Liabilities and Net Assets</b>		
Accounts payable	\$ 26,081	\$ 21,217
Accrued expenses and other liabilities	27,293	25,244
Notes payable	<u>1,525</u>	<u>2,467</u>
<b>Total Liabilities</b>	<b>54,899</b>	<b>48,928</b>
<b>Net Assets:</b>		
Unrestricted	26,051	21,495
Temporarily restricted	470,882	546,620
Permanently restricted	<u>3,394</u>	<u>3,390</u>
<b>Total Net Assets</b>	<b><u>500,327</u></b>	<b><u>571,505</u></b>
<b>Total Liabilities and Net Assets</b>	<b><u>\$ 555,226</u></b>	<b><u>\$ 620,433</u></b>

See accompanying notes.

PATH AND SUBSIDIARIES

**Consolidated Statement of Activities and Changes in Net Assets  
For the Year Ended December 31, 2016  
(In Thousands)**

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
<b>Operating Revenues:</b>				
Grants, contracts and contributions-				
U.S. government	\$ -	\$ 105,877	\$ -	\$ 105,877
Other government		22,473		22,473
Private foundations		117,148		117,148
Other awards and in-kind		26,848		26,848
Private campaign contributions	8,328	4,007	4	12,339
	8,328	276,353	4	284,685
Other income-				
Investment income	811	3,199		4,010
Other	399			399
	1,210	3,199		4,409
Net assets released from restrictions-				
Satisfaction of program restrictions	321,182	(321,182)		
Private campaign - pledges released from restriction	1,204	(1,204)		
	322,386	(322,386)		
<b>Total Operating Revenues</b>	<b>331,924</b>	<b>(42,834)</b>	<b>4</b>	<b>289,094</b>
<b>Expenses:</b>				
Program services	265,778			265,778
Support services-				
Fundraising	4,143			4,143
Bid and proposal	3,667			3,667
Management and general	51,673			51,673
<b>Total Expenses</b>	<b>325,261</b>			<b>325,261</b>
<b>Change in Net Assets From Operations</b>	<b>6,663</b>	<b>(42,834)</b>	<b>4</b>	<b>(36,167)</b>
<b>Nonoperating Activity:</b>				
Loss on foreign currency exchange	(2,107)			(2,107)
Refund of unused project funds (Note 16)		(32,904)		(32,904)
<b>Total Change in Net Assets</b>	<b>4,556</b>	<b>(75,738)</b>	<b>4</b>	<b>(71,178)</b>
Net assets, beginning of year	21,495	546,620	3,390	571,505
<b>Net Assets, End of Year</b>	<b>\$ 26,051</b>	<b>\$ 470,882</b>	<b>\$ 3,394</b>	<b>\$ 500,327</b>

See accompanying notes.

PATH AND SUBSIDIARIES

**Consolidated Statement of Activities and Changes in Net Assets  
For the Year Ended December 31, 2015  
(In Thousands)**

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
<b>Operating Revenues:</b>				
Grants, contracts and contributions-				
U.S. government	\$ -	\$ 96,680	\$ -	\$ 96,680
Other government		16,231		16,231
Private foundations		137,559		137,559
Other awards and in-kind		11,990		11,990
Private campaign contributions	5,715	4,489	3	10,207
	<u>5,715</u>	<u>266,949</u>	<u>3</u>	<u>272,667</u>
Other income-				
Investment income	437	834		1,271
Other	2,207			2,207
	<u>2,644</u>	<u>834</u>		<u>3,478</u>
Net assets released from restrictions-				
Satisfaction of program restrictions	279,054	(279,054)		
Private campaign - pledges released from restriction	1,235	(1,235)		
	<u>280,289</u>	<u>(280,289)</u>		
<b>Total Operating Revenues</b>	<b>288,648</b>	<b>(12,506)</b>	<b>3</b>	<b>276,145</b>
<b>Expenses:</b>				
Program services	234,994			234,994
Support services-				
Fundraising	3,569			3,569
Bid and proposal	2,441			2,441
Management and general	43,890			43,890
<b>Total Expenses</b>	<b>284,894</b>			<b>284,894</b>
<b>Change in Net Assets From Operations</b>	<b>3,754</b>	<b>(12,506)</b>	<b>3</b>	<b>(8,749)</b>
<b>Nonoperating Activity:</b>				
Loss on foreign currency exchange	(2,438)			(2,438)
Refund of unused project funds (Note 16)		(33,879)		(33,879)
<b>Total Change in Net Assets</b>	<b>1,316</b>	<b>(46,385)</b>	<b>3</b>	<b>(45,066)</b>
Net assets, beginning of year	20,179	593,005	3,387	616,571
<b>Net Assets, End of Year</b>	<b>\$ 21,495</b>	<b>\$ 546,620</b>	<b>\$ 3,390</b>	<b>\$ 571,505</b>

See accompanying notes.

**PATH AND SUBSIDIARIES**

**Consolidated Statement of Functional Expenses  
For the Year Ended December 31, 2016  
(In Thousands)**

	Program Services			
	Essential Medicines	Public Health	International Development	Technology Development and Introduction
Salaries	\$ 20,690	\$ 23,278	\$ 9,033	\$ 8,422
Fringe benefits and payroll tax	6,433	7,892	2,879	2,625
Sub-agreements	38,166	14,704	18,819	4,907
Sub-contracts	17,440	5,143	3,147	1,145
Professional services	1,837	2,430	809	742
Consultants	90	727	5,163	452
Occupancy	3,497	3,747	1,514	1,610
Relocation and moving	73	284	112	80
Travel	4,533	9,482	4,959	1,243
Meetings, education and workshops	575	5,637	3,320	176
Printing and copying	32	1,150	506	37
Telecommunications	301	612	209	58
Postage and freight	116	421	95	153
Supplies	124	4,161	857	772
Equipment rental and maintenance	100	891	716	293
Project procurement	7	1,787	668	151
In-kind contributions		5		
Insurance	145	25	3	7
Other	18	436	1,797	80
	<b>\$ 94,177</b>	<b>\$ 82,812</b>	<b>\$ 54,606</b>	<b>\$ 22,953</b>

See accompanying notes.



		Support Services					
Other	Total Program Services	Management and General	Fundraising	Bid and Proposal	Total		
\$ 4,359	\$ 65,782	\$ 23,358	\$ 1,872	\$ 1,855	\$ 92,867		
1,352	21,181	7,271	585	595	29,632		
400	76,996				76,996		
1,069	27,944	1,408	427	23	29,802		
1,029	6,847	4,817	126	293	12,083		
70	6,502	1,092	84	14	7,692		
740	11,108	4,378	332	314	16,132		
34	583	98		2	683		
1,052	21,269	2,150	92	498	24,009		
286	9,994	605	354	47	11,000		
51	1,776	208	24	1	2,009		
81	1,261	280	7	7	1,555		
16	801	82	15	1	899		
67	5,981	352	8	1	6,342		
112	2,112	1,138	29	2	3,281		
500	3,113				3,113		
	5	3,239	6		3,250		
	180	239			419		
12	2,343	958	182	14	3,497		
<b>\$ 11,230</b>	<b>\$ 265,778</b>	<b>\$ 51,673</b>	<b>\$ 4,143</b>	<b>\$ 3,667</b>	<b>\$ 325,261</b>		

**PATH AND SUBSIDIARIES**

**Consolidated Statement of Functional Expenses  
For the Year Ended December 31, 2015  
(In Thousands)**

	Program Services			
	Essential Medicines	Public Health	International Development	Technology Development and Introduction
Salaries	\$ 21,972	\$ 19,557	\$ 7,653	\$ 9,471
Fringe benefits and payroll tax	6,027	6,152	2,466	2,696
Sub-agreements	33,166	17,584	13,995	4,917
Sub-contracts	15,720	4,347	3,457	2,956
Professional services	1,489	2,232	645	844
Consultants	155	423	960	923
Occupancy	3,669	3,138	1,379	1,807
Relocation and moving	73	107	89	16
Travel	5,026	7,818	3,271	1,474
Meetings, education and workshops	474	3,437	1,790	130
Printing and copying	63	601	383	13
Telecommunications	361	685	257	69
Postage and freight	214	289	79	112
Supplies	170	2,615	266	1,026
Equipment rental and maintenance	170	790	359	412
Project procurement	119	875	701	406
In-kind contributions	622	20	487	
Patent amortization		45		
Insurance	164	21	6	7
Other	225	352	1,408	35
	<b>\$ 89,879</b>	<b>\$ 71,088</b>	<b>\$ 39,651</b>	<b>\$ 27,314</b>

See accompanying notes.

Support Services

Other	Total Program Services	Management and General	Fundraising	Bid and Proposal	Total
\$ 2,652	\$ 61,305	\$ 21,865	\$ 1,573	\$ 1,275	\$ 86,018
752	18,093	6,303	449	374	25,219
225	69,887				69,887
867	27,347	510	585	46	28,488
569	5,779	2,999	130	192	9,100
53	2,514	1,064	41	8	3,627
464	10,457	4,178	274	217	15,126
17	302	55		2	359
619	18,208	1,674	63	288	20,233
218	6,049	350	257	11	6,667
34	1,094	206	18	2	1,320
57	1,429	325	6	7	1,767
5	699	103	10	1	813
16	4,093	338	16	1	4,448
23	1,754	1,577	29		3,360
101	2,202	15			2,217
	1,129	1,220	3		2,352
	45				45
	198	276			474
390	2,410	832	115	17	3,374
<b>\$ 7,062</b>	<b>\$ 234,994</b>	<b>\$ 43,890</b>	<b>\$ 3,569</b>	<b>\$ 2,441</b>	<b>\$ 284,894</b>

**PATH AND SUBSIDIARIES**

**Consolidated Statements of Cash Flows  
For the Years Ended December 31, 2016 and 2015  
(In Thousands)**

	<u>2016</u>	<u>2015</u>
<b>Cash Flows From Operating Activities:</b>		
Change in net assets	\$ (71,178)	\$ (45,066)
Adjustments to reconcile change in net assets to net cash used by operating activities-		
Depreciation and amortization	3,217	3,275
Unrealized (gain) loss on investments	(897)	1,365
Gain on hedging activity	(1,407)	
Loss (gain) on sale and disposal of equipment	81	(16)
In-kind software contribution		(6,379)
Contributions restricted for endowment	(4)	(3)
Changes in assets and liabilities:		
Contributions and awards receivable	30,089	19,389
Prepaid expenses and other	2,263	795
Other receivables	(221)	216
Accounts payable	4,842	(3,801)
Accrued expenses and other liabilities	2,049	(1,938)
<b>Net Cash Used by Operating Activities</b>	<b>(31,166)</b>	<b>(32,163)</b>
<b>Cash Flows From Investing Activities:</b>		
Purchases of furniture, equipment and leasehold improvements	(1,417)	(1,423)
Proceeds from sale of equipment	45	33
Net proceeds from hedging activity	968	
Purchases of investments	(65,968)	(69,459)
Proceeds from maturity/sales of investments	84,062	67,836
<b>Net Cash Provided (Used) by Investing Activities</b>	<b>17,690</b>	<b>(3,013)</b>
<b>Cash Flows From Financing Activities:</b>		
Payments on notes payable	(942)	(937)
Proceeds from contributions restricted for endowment	4	3
<b>Net Cash Used by Financing Activities</b>	<b>(938)</b>	<b>(934)</b>
<b>Net Change in Cash and Cash Equivalents</b>	<b>(14,414)</b>	<b>(36,110)</b>
Cash and cash equivalents, beginning of year	118,096	154,206
<b>Cash and Cash Equivalents, End of Year</b>	<b>\$ 103,682</b>	<b>\$ 118,096</b>
<b>Supplementary Disclosure of Cash Flow Information:</b>		
Cash paid during the year for interest	\$ 41	\$ 58
Property and equipment purchases included in accounts payable	\$ 22	\$ -

See accompanying notes.

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 1 - Organization and Summary of Accounting Policies

**Organization** - PATH and its Subsidiaries (collectively, the Organization) is a 501(c)(3) nonprofit, nongovernmental organization incorporated in the State of Washington. PATH is an international organization that drives transformative innovation to save lives and improve health, especially among women and children. PATH accelerates innovation across five platforms - vaccines, drugs, diagnostics, devices and systems and service innovations - that harness its entrepreneurial insight, scientific and public health expertise and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together they deliver measurable results that disrupt the cycle of poor health.

For 40 years, PATH has been a pioneer in translating bold ideas into breakthrough health solutions, with a focus on child survival, maternal and reproductive health, and infectious diseases. With headquarters in Seattle, Washington, PATH has close to 1,500 employees and offices in more than 20 countries. PATH receives support from foundations, governments, multilateral agencies, nongovernmental organizations, universities, corporations and individuals. Learn more at [www.path.org](http://www.path.org).

**Basis of Presentation** - The consolidated financial statements of the Organization have been prepared on the accrual basis of accounting under accounting principles generally accepted in the United States of America (U.S. GAAP). The consolidated financial statements include the accounts of PATH and PATH's controlled subsidiaries, including: PATH Vaccine Solutions (PVS), a 501(c)(3) nonprofit corporation formed to advance the development of vaccines to improve the health of children worldwide; Foundation for Appropriate Technologies in Health - Switzerland (FATH), a Swiss Foundation; and PATH Drug Solutions (PDS), a 501(c)(3) nonprofit corporation that advances the development of medicines to improve the health of children worldwide. All inter-entity accounts and transactions have been eliminated in consolidation.

For the purposes of financial reporting, the Organization classifies resources into three net asset categories pursuant to any donor-imposed restrictions. Accordingly, the net assets of the Organization are classified and reported as follows:

Unrestricted Net Assets - Net assets that are not subject to donor-imposed stipulations.

Temporarily Restricted Net Assets - Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Organization and/or the passage of time.

Permanently Restricted Net Assets - Net assets restricted by donor-imposed stipulations to be invested in perpetuity. The investment income from these funds is available for current use.

Support and revenue are reported as increases in unrestricted net assets unless the use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Temporary restrictions expire when the donor-stipulated purpose has been fulfilled and/or the donor-stipulated time period has elapsed. Expirations of temporary restrictions result in the reclassification of temporarily restricted net assets to unrestricted net assets and are reported in the consolidated statements of activities and changes in net assets as net assets released from restrictions.

**Cash and Cash Equivalents** - For purposes of the consolidated statements of cash flows, the Organization considers all highly liquid debt instruments purchased with an original maturity of three months or less, other than those held in the Organization's investment portfolio, to be cash equivalents.

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 1 - Continued

**Investments** - Investments in equity securities with readily determinable market values and all debt securities are recorded at fair value. Unrealized and realized gains and losses on these investments are reported in the consolidated statements of activities and changes in net assets. Securities are generally held in custodial investment accounts administered by certain financial institutions.

Investment securities, in general, are exposed to various risks, including interest rate, credit and overall market volatility. Due to the level of risk associated with certain long-term investments, it is possible that changes in the values of these investments will occur in the near term and that such changes could materially affect the amounts reported in the consolidated statements of financial position.

Investment income consists primarily of income earned on cash, cash equivalents and investments and is recognized as earned. Where directed by the donor or grantor, investment income on award advances is credited to specific restricted funds for future use as specified in the award agreement. All other interest income earned is credited to other restricted and unrestricted fund balances as is appropriate.

**Fair Value of Financial Instruments** - Financial instruments reported at fair value on a recurring basis include investments. Financial instruments not reported at fair value on a recurring basis include receivables, accounts payable and notes payable. The carrying amounts of these financial instruments approximate fair value.

**Contributions and Awards Receivable** - Contributions and awards receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable uncollectible amounts through a charge to expense and a credit to a valuation allowance based on its assessment of the current status of individual accounts. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts, grants or contributions receivable.

**Furniture, Equipment and Leasehold Improvements** - The Organization capitalizes furniture, equipment and leasehold improvements with a cost of \$5,000 or greater. The cost of furniture and equipment is depreciated over the estimated useful life of the asset and is computed using the straight-line method. Leasehold improvements are amortized over the lives of the respective leases or the service lives of the improvements, whichever is shorter. Maintenance and repairs are charged to expense as incurred. Computer software purchases of \$25,000 or greater are capitalized and depreciated. Internally developed software and internally developed enhancements and modifications to existing or purchased software that result in additional functionality with a total development cost in excess of \$500,000 are capitalized and depreciated.

**Vulnerability From Certain Concentrations** - Financial instruments that potentially subject the Organization to concentrations of credit and market risk consist primarily of cash and cash equivalents and investments. Cash and cash equivalents and investments held by financial institutions at times exceed Federal Deposit Insurance Corporation and Securities Investor Protection Corporation insured limits.

For the years ended December 31, 2016 and 2015, total revenues, gains and other support of 50% and 51%, respectively, and gross contributions and awards receivable of 43% and 55%, respectively, were from one private foundation.

For the years ended December 31, 2016 and 2015, 31% and 26%, respectively, of the Organization's total revenues, gains and other support consists of awards from agencies of the United States government, and 24% and 20%, respectively, of gross contributions and awards receivable is from agencies of the United States government.

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 1 - Continued

Management is aware of the related vulnerabilities but does not anticipate material losses in connection with these concentrations. Management continues to seek improved diversification from donors and funding sources.

**Contributions and Awards Revenue Recognition** - Unconditional contributions and awards from United States and foreign government agencies, foundations and public and private funders are recognized as temporarily restricted revenue at the time committed or obligated, provided the donor has identified a restriction on the use of the funds. Revenue from contracts is recognized at the time the service or good is provided.

**Donated Goods and Services** - Donations of goods, including property and equipment and software licenses, are recorded as support at their estimated fair values at the date of donation. Such donations are reported as unrestricted support unless the donor has restricted the donated asset to a specific purpose. Donated services are recognized if the services received (i) create or enhance nonfinancial assets or (ii) require specialized skills, are provided by individuals possessing those skills and would need to be purchased if not provided by donation.

In-kind donations received totaled approximately \$0.1 million and \$7.9 million for the years ended December 31, 2016 and 2015, respectively. In 2015, two-year software licenses valued at \$6.4 million were recorded as temporarily restricted in-kind contributions and are being released from restrictions over the two-year time period. The licenses were recorded as prepaid expense and are amortized over the two years.

Amortization and release from restriction totaled \$3.2 million and \$1 million for the years ended December 31, 2016 and 2015, respectively. In-kind expenses totaled \$3.3 million and \$2.4 million during the years ended December 31, 2016 and 2015, respectively.

**Functional Allocation of Expenses** - The costs of providing the various programs and other activities have been summarized on a functional basis in the consolidated statements of activities and changes in net assets. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

**Collaborations** - Awards, contracts and temporarily restricted contributions are used to fund projects related to global health. In connection with these projects, the Organization works with collaborating partners to assess health problems, identify and implement solutions and evaluate results. Accordingly, the Organization enters into funding agreements and cooperative agreements with these collaborating partners including international agencies, ministries of health, nongovernmental organizations, commercial entities and universities, et cetera. Subagreements and subcontracts awarded from these projects are funded by temporarily restricted contributions from other organizations and recorded as expense, which totaled \$107.0 million and \$98.4 million for the years ended December 31, 2016 and 2015, respectively.

**Tax Exempt Status** - The Internal Revenue Service has determined that PATH, PVS and PDS are exempt from federal income taxes under provisions of Section 501(c)(3) of the Internal Revenue Code (IRC). They are classified as organizations that are not private foundations under Section 501(a) of the IRC. PATH, as an independent nonprofit foundation within the meaning of Articles 80 et seq of the Swiss Civil Code, has been granted tax exemption by the Department of Finance.

**Foreign Currency Translation** - Substantially all assets and liabilities of the Organization that are held in foreign currencies are translated at year end exchange rates. Revenues, gains and other support and expenses are translated at the average monthly exchange rates during the year. Gains and losses from foreign currency translation for the year are included in the consolidated statements of activities and changes in net assets.

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 1 - Continued

**Use of Estimates** - The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Reclassifications** - Certain reclassifications have been made to 2015 amounts to conform to the 2016 presentation. The reclassifications have no effect on the previously reported total assets, liabilities, net assets, or change in net assets for 2015.

**Subsequent Events** - The Organization has evaluated subsequent events through May 31, 2017, the date on which the consolidated financial statements were available to be issued.

#### Note 2 - Cash and Cash Equivalents

Cash and cash equivalents consisted of the following at December 31:

	(In Thousands)	
	2016	2015
Money market accounts and other cash equivalents	\$ 1,335	\$ 100,428
Cash	102,347	17,668
	<u>\$ 103,682</u>	<u>\$ 118,096</u>

Cash and cash equivalents held in bank accounts outside of the United States totaled \$11.3 million and \$17.9 million at December 31, 2016 and 2015, respectively. When specified by funding agreement, the Organization holds project-related funds in separate bank accounts.

#### Note 3 - Investments

Investments consisted of the following at December 31:

	(In Thousands)	
	2016	2015
Corporate bonds	\$ 120,140	\$ 121,047
U.S., state and foreign government securities	32,270	52,530
Asset-backed securities	21,912	18,560
Equity securities and mutual funds	5,496	5,454
Money market investment funds	1,879	1,303
	<u>\$ 181,697</u>	<u>\$ 198,894</u>



## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 3 - Continued

The return on cash and investments was comprised of the following for the years ended December 31:

	(In Thousands)	
	2016	2015
Interest and dividends	\$ 2,889	\$ 2,232
Unrealized gains/(losses)	897	(1,365)
Realized gains	224	404
	<u>\$ 4,010</u>	<u>\$ 1,271</u>

#### Note 4 - Fair Value Measurements

U.S. GAAP provides a framework for measuring fair value. To increase consistency and comparability in fair value measurements, the framework requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.

The framework uses a three-level valuation hierarchy based on observable and nonobservable inputs. Observable inputs consist of data obtained from independent sources. Nonobservable inputs reflect market assumptions. These two types of inputs are used to create the fair value hierarchy, giving preference to observable inputs.

Assets and liabilities classified as Level 1 have fair values based on unadjusted quoted market prices for identical instruments in active markets. Assets and liabilities classified as Level 2 have fair values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in inactive markets, or model-derived valuations whose inputs are observable. Assets and liabilities classified as Level 3 have fair values based on value drivers that are unobservable.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2016 and 2015.

Money Market Investment Funds - Valued at cost plus accrued interest, which approximates fair value.

Equity and Debt Mutual Funds - Valued at quoted market prices in active markets, which represent the net asset value (NAV) of shares held by the Organization at year-end.

Equity Securities - Valued at the closing price reported on the active market on which the securities are traded.

Debt Securities - Valued using bid evaluations from similar instruments in actively traded markets.

Foreign Exchange Derivative Contracts - Valued based primarily on the exchange rates effective at the measurement date.

PATH AND SUBSIDIARIES

Notes to Consolidated Financial Statements  
For the Years Ended December 31, 2016 and 2015

Note 4 - Continued

Assets recorded at fair value on a recurring basis were as follows at December 31, 2016:

	(In Thousands)		Total
	Level 1	Level 2	
Equity securities and equity mutual funds-			
Equity securities:			
Biopharmaceuticals	\$ 14		\$ 14
Equity mutual funds:			
Large blend	3,973		3,973
Large value	1,509		1,509
Total equity securities and equity mutual funds	5,496		5,496
Debt securities and debt mutual funds-			
Debt securities:			
U.S. government	29,070		29,070
Foreign government		3,200	3,200
Corporate		116,729	116,729
Asset-backed securities		21,912	21,912
Debt mutual funds:			
Multi-sector bond	3,411		3,411
Total debt securities and debt mutual funds	32,481	141,841	174,322
Money market investment funds	1,879		1,879
Total investments	39,856	141,841	181,697
Foreign exchange derivative contracts		439	439
<b>Total Assets at Fair Value</b>	<b>\$ 39,856</b>	<b>\$ 142,280</b>	<b>\$ 182,136</b>

PATH AND SUBSIDIARIES

Notes to Consolidated Financial Statements  
For the Years Ended December 31, 2016 and 2015

Note 4 - Continued

Assets recorded at fair value on a recurring basis were as follows at December 31, 2015:

	(In Thousands)		
	Level 1	Level 2	Total
Equity securities and equity mutual funds-			
Equity securities:			
Biopharmaceuticals	\$ 19	\$ -	\$ 19
Equity mutual funds:			
Large blend	3,557		3,557
Large value	1,878		1,878
Total equity securities and equity mutual funds	5,454		5,454
Debt securities and debt mutual funds-			
Debt securities:			
U.S. government	45,835		45,835
Foreign government		6,695	6,695
Corporate		117,605	117,605
Asset-backed securities		18,560	18,560
Debt mutual funds:			
Multi-sector bond	3,442		3,442
Total debt securities and debt mutual funds	49,277	142,860	192,137
Money market investment funds	1,303		1,303
<b>Total Assets at Fair Value</b>	<b>\$ 56,034</b>	<b>\$ 142,860</b>	<b>\$ 198,894</b>

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

#### Note 5 - Contributions and Awards Receivable

Contributions and awards receivable consisted of the following at December 31:

	(In Thousands)	
	2016	2015
Due in less than one year	\$ 188,767	\$ 212,293
Due in one to five years	61,384	67,869
	250,151	280,162
Less present value discount (0.3% - 4.8%)	(836)	(569)
Less allowance for doubtful accounts	(885)	(1,074)
	<u>\$ 248,430</u>	<u>\$ 278,519</u>

Awards from the United States government and certain nongovernmental organizations are recorded as revenue when obligated, which may not reflect the full amount awarded. The total amount of unobligated awards pending for active projects was \$466.7 million and \$381.9 million at December 31, 2016 and 2015, respectively. At December 31, 2016 and 2015, 59% and 58%, respectively, of the Organization's unobligated awards were from one private foundation. At December 31, 2016 and 2015, 25%, of the Organization's unobligated awards were from one agency of the United States government.

#### Note 6 - Furniture, Equipment and Leasehold Improvements

The Organization funds purchases of furniture, equipment and leasehold improvements from two sources: the capital fund, a designated reserve of unrestricted net assets; or temporarily restricted project funds.

Furniture, equipment and leasehold improvements consisted of the following at December 31:

	2016 (In Thousands)		
	Capital Fund	Project Funds	Total
Furniture	\$ 3,589	\$ -	\$ 3,589
Equipment	4,180	6,994	11,174
Leasehold improvements	20,681	67	20,748
	28,450	7,061	35,511
Less accumulated depreciation and amortization	(16,735)	(5,325)	(22,060)
	11,715	1,736	13,451
Construction in process	175		175
	<u>\$ 11,890</u>	<u>\$ 1,736</u>	<u>\$ 13,626</u>

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

#### Note 6 - Continued

	2015 (In Thousands)		
	Capital Fund	Project Funds	Total
Furniture	\$ 3,589	\$ -	\$ 3,589
Equipment	4,222	7,296	11,518
Leasehold improvements	20,440	67	20,507
	28,251	7,363	35,614
Less accumulated depreciation and amortization	(14,940)	(5,144)	(20,084)
	<u>\$ 13,311</u>	<u>\$ 2,219</u>	<u>\$ 15,530</u>

#### Note 7 - Line of Credit

The Organization has a revolving line of credit for up to \$1 million with a commercial bank for working capital purposes available through June 30, 2017. Interest on the line is at LIBOR plus 1.25%. The line of credit is secured by the Organization's personal property. The credit facility available to the Organization is reduced by Standby Letters of Credit (SBLC) associated with its lease commitments. PATH has a SBLC for \$234,300 at December 31, 2016 and 2015. No amounts were outstanding under the line of credit or SBLC at December 31, 2016 or 2015.

#### Note 8 - Notes Payable

Notes payable consisted of the following at December 31:

	(In Thousands)	
	2016	2015
Note payable to a commercial bank maturing February 1, 2018. Interest payments accrue at 1.86%. Principal is payable in monthly installments of \$56,944. The note is secured by the Organization's personal property. The note includes certain restrictive covenants, including the requirement for the Organization to maintain certain financial ratios.	\$ 797	\$ 1,480
Program-related investment from a private foundation in the form of a note payable maturing November 2019. Interest is paid at a 2% fixed rate. Quarterly principal and interest payments of \$69,114 are required. The note is secured by the Organization's trade fixtures, equipment and furnishings. The note includes certain restrictive covenants, including the requirement for the Organization to maintain certain financial ratios.	728	987
	<u>\$ 1,525</u>	<u>\$ 2,467</u>

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 8 - Continued

Maturities of notes payable are as follows:

For the Year Ending December 31,	(In Thousands)
2017	\$ 947
2018	383
2019	195
	<u>\$ 1,525</u>

Interest expense on notes payable totaled \$41,000 and \$58,000 for the years ended December 31, 2016 and 2015, respectively.

#### Note 9 - Self-Insurance Reserve

The Organization maintains a research insurance program made up of a Self-Insured Retention (SIR) reserve fund and an excess insurance policy. The Organization's SIR program covers claims up to \$125,000 per incident and is funded by allocations to programs that are conducting clinical trials involving human subjects. As of December 31, 2016 and 2015, \$2.1 million has been funded and set aside in the reserve. It is anticipated that additional planned annual allocations and interest income will add to the reserve going forward. Additionally, the Organization carries an excess insurance policy to cover any potential claims from \$125,000 to \$10 million.

#### Note 10 - Unrestricted Net Assets

Unrestricted net assets consisted of the following at December 31:

	(In Thousands)	
	2016	2015
Capital fund	\$ 4,000	\$ 3,700
Catalyst fund	10,562	6,900
Board designated quasi-endowment fund	3,334	3,477
Self-insured retention reserve	2,115	2,102
Undesignated	6,040	5,316
	<u>\$ 26,051</u>	<u>\$ 21,495</u>

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 10 - Continued

The following is a description of board designated unrestricted net assets:

Capital Fund - Represents the portion of net assets attributed to the net book value of fixed assets and amounts designated for future purchases of fixed assets, net of any related loan balance.

Catalyst Fund - Represents a fund established by the Organization that consists of donor contributions that serve as a key source of innovation funding: funds that support new initiatives, leverage major grants and meet critical organizational needs.

Board Designated Endowment - The endowment that is included in unrestricted net assets represents amounts designated by the Board.

Self-Insured Retention Reserve - The amount funded to date to pay the Organization's share of any claims resulting from settlement or judgment of actions as a result of clinical trials (Note 9).

#### Note 11 - Temporarily Restricted Net Assets

Temporarily restricted net assets were available for the following purposes at December 31:

	(In Thousands)	
	2016	2015
Privately funded projects	\$ 347,205	\$ 422,579
U.S. government funded projects	52,512	51,430
Project funds generated from interest earnings	28,698	26,740
International government funded projects	21,536	21,561
International bi-lateral funded projects	6,343	8,756
Prepaid licenses (see Note 1)	2,416	5,464
Project equipment	1,771	2,133
Endowment earnings	2,612	2,030
Private campaign - donor restricted	4,344	3,242
Unpaid private campaign pledges	3,445	2,685
	<u>\$ 470,882</u>	<u>\$ 546,620</u>

Restricted funds are available for projects specified by donors and are focused primarily on global health initiatives.

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

#### Note 12 - Endowment

The Organization's endowment consists of a number of funds established for a variety of purposes. Its endowment includes both donor-restricted endowment funds and funds designated by the Board to function as an endowment (quasi-endowment). As required by U.S. GAAP, net assets associated with endowment funds, including quasi-endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The Board of Directors of the Organization has reviewed the Washington State Prudent Management of Institutional Funds Act (PMIFA) and, having reviewed its rights and obligations thereunder, has determined that it is desirable to preserve, on a long-term basis, the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this determination, the Organization classifies as permanently restricted net assets the original value of gifts to the permanent endowment, the original value of subsequent gifts to the permanent endowment, and accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the Organization in a manner consistent with the standard of prudence prescribed by PMIFA.

In accordance with PMIFA, the Organization considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: 1) duration and preservation of the endowment fund; 2) the purposes of the Organization and the endowment fund; 3) general economic conditions; 4) effect of inflation or deflation; 5) the expected total return from income and the appreciation of investments; 6) other resources of the Organization; and, 7) the investment policy of the Organization.

Endowment net assets consisted of the following at December 31:

	2016 (In Thousands)			Total
	Unrestricted	Temporarily Restricted	Permanently Restricted	
Donor restricted endowment funds	\$ -	\$ 2,612	\$ 3,394	\$ 6,006
Board designated quasi-endowment funds	3,334			3,334
	<u>\$ 3,334</u>	<u>\$ 2,612</u>	<u>\$ 3,394</u>	<u>\$ 9,340</u>

  

	2015 (In Thousands)			Total
	Unrestricted	Temporarily Restricted	Permanently Restricted	
Donor restricted endowment funds	\$ -	\$ 2,030	\$ 3,390	\$ 5,420
Board designated quasi-endowment funds	3,477			3,477
	<u>\$ 3,477</u>	<u>\$ 2,030</u>	<u>\$ 3,390</u>	<u>\$ 8,897</u>



PATH AND SUBSIDIARIES

Notes to Consolidated Financial Statements  
For the Years Ended December 31, 2016 and 2015

Note 12 - Continued

Changes to endowment net assets were as follows for the years ended December 31, 2016 and 2015:

	(In Thousands)			Total
	Unrestricted	Temporarily Restricted	Permanently Restricted	
Endowment net assets, January 1, 2015	\$ 3,499	\$ 2,518	\$ 3,387	\$ 9,404
Endowment investment return-				
Interest and dividends	93	143		236
Realized and unrealized losses	(115)	(179)		(294)
Total endowment investment return	(22)	(36)		(58)
Contributions			3	3
Earnings appropriated for expenditure		(452)		(452)
<b>Endowment Net Assets, December 31, 2015</b>	<b>3,477</b>	<b>2,030</b>	<b>3,390</b>	<b>8,897</b>
Endowment investment return-				
Interest and dividends	38	181		219
Realized and unrealized gain (losses)	(181)	871		690
Total endowment investment return	(143)	1,052		909
Contributions			4	4
Earnings appropriated for expenditure		(470)		(470)
<b>Endowment Net Assets, December 31, 2016</b>	<b>\$ 3,334</b>	<b>\$ 2,612</b>	<b>\$ 3,394</b>	<b>\$ 9,340</b>

The Organization has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Organization must hold in perpetuity or for donor-specified periods as well as board designated funds. Under this policy, as approved by the Board of Directors, the endowment assets are invested in mutual funds to ensure a broad diversification among investment styles, sectors, industries, market capitalizations and credit quality. These vehicles offer the advantages of economies of scale, greater liquidity, broader diversification, cost efficiency, lower transaction costs and low minimum investment requirements not available through separate account management.

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 12 - Continued

The performance objective for the total endowment investment portfolio is to achieve an annualized investment return, net of fees, which will exceed a composite index composed of 40% Barclays Capital Aggregate Index and 60% S&P 500 Index. The Organization expects its endowment funds, over time, to provide an average rate of return of approximately 5% annually. Actual returns in any given year may vary from this amount based on current market conditions.

To satisfy its long-term rate-of-return objectives, the Organization relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Organization targets a diversified asset allocation between two asset classes: 40% fixed income and 60% equity investments to achieve its long-term return objectives within prudent risk constraints.

The Organization has established an endowment spending policy for appropriating a maximum distribution in support of PATH's programs each year. In establishing this policy, the Organization considered the long-term expected return on its endowment and the need for that return to provide additional protection for any necessary adjustment to the value of the endowment for inflation. In order to sustain the real value of the endowment, the long-term return of the endowment should meet or exceed spending plus inflation as measured by an appropriate benchmark, such as the Consumer Price Index (CPI). To protect the essential value of the endowment against the expected impact of inflation, the Finance Committee sets a payout rate for the endowment's income that provides a prudent rate of real growth of endowment funds while also providing a relatively constant funding stream in support of PATH's current expenditures for programs.

In determining each year's level of distribution, PATH will be governed by a spending policy which seeks to distribute up to 5% of the market value of the endowment investment portfolio, calculated based on the prior year's ending balance. This is consistent with the Organization's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return.

#### Note 13 - Project Revenue

The Organization has received several awards from The Department for International Development (DFID), United Kingdom of Great Britain and Northern Ireland, to support specific projects. DFID requires separate disclosure of revenue recognized in the Organization's financial statements. Revenue recognized, including releases of restriction, for each of these projects was as follows for the year ended December 31, 2016:

	<u>(In Thousands)</u>
Nutrition Embedding Evaluation Project (NEEP)	\$ 1,111
Product Development Partnership (PDP) Arrangement for 2010-2015- Meningococcal Conjugate Vaccines	1,549
Reproductive Health Supplies Coalition- Developing Affordable, Quality Reproductive Health Commodities: Purchase Order 40068171	1,466
Technical Assistance for Nutrition 2016 to 2020	121
Maximizing the Quality of Scaling up Nutrition Programmes	3,285
Product Development Partnership Programme 2013 to 2018	7,223
	<u>\$ 14,755</u>

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 13 - Continued

Revenue for these awards is released from restriction as related allowable project costs are incurred and is included in contribution and award revenue on the consolidated statements of activities and changes in net assets.

#### Note 14 - Employee Benefits

The Organization sponsors a defined contribution 401(k) plan (the Plan). Under the Plan, eligible PATH employees may elect to contribute up to 75% of their pre-tax compensation, subject to certain limits under the IRC. The Organization will match the employee's contribution monthly at a ratio of 1:1 for the first 2%, and 1:2 for the next 4%, with a maximum employer contribution equal to 4% of pre-tax salary. Employer matching contributions to the Plan are fully vested after one year of completed service. Employee optional contributions in the Plan vest immediately. In addition, the Organization may make a voluntary employer contribution of up to 8% of employees' base compensation. Voluntary employer contributions to the Plan vest at a rate of 20% for each completed year of service. All regular U.S. hire employees are eligible to enter the Plan on the first of the month after completing three months of employment. The Organization also offers an optional Roth 401(k) plan.

Within the various countries in which PATH operates outside the United States, most employees are citizens of the host country. These employees are generally not eligible for PATH's defined contribution plan; however, they are eligible for certain local government sponsored plans appropriate for that country.

Employer contributions for both U.S.-based plans totaled \$7.8 million and \$6.7 million for the years ended December 31, 2016 and 2015, respectively. Total global pension costs totaled \$9.3 million and \$7.9 million for the years ended December 31, 2016 and 2015, respectively.

#### Note 15 - Commitments and Contingencies

**Operating Leases** - A summary of annual noncancelable minimum commitments under operating leases for office space and equipment is as follows:

For the Year Ending December 31,	<u>(In Thousands)</u>
2017	\$ 8,413
2018	7,624
2019	7,650
2020	7,850
2021	6,724
Thereafter	<u>16,251</u>
	<u><u>\$ 54,512</u></u>

Rental expense was \$9.8 million and \$9.2 million for the years ended December 31, 2016 and 2015, respectively.

**Potential Disallowed Costs** - Expenses incurred under certain programs are subject to audit by the awarding agencies. If, as a result of such audit, certain expenses incurred are determined to be nonreimbursable, the Organization may be liable for repayment of disallowed expenses previously claimed or received.

## PATH AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015

---

#### Note 15 - Continued

**Contingencies** - In the normal course of business, the Organization has various claims in process, matters in litigation and other contingencies. In management's opinion, the outcome from these matters will not materially impact the Organization's financial position or results of activities.

#### Note 16 - Refund of Unused Project Funds

From time to time, unspent award funds may be returned to a funder for a variety of reasons including, but not limited to, early termination of a project by a funder, or a reduction in funds required to accomplish a project's scope of work. Project funds were returned to funders as follows for the years ended December 31, 2016 and 2015:

	(In Thousands)	
	2016	2015
Early Terminations - PDS projects	\$ -	\$ 18,251
Early Terminations - Other projects	10,577	8,650
Reductions in funds needed to accomplish the scope of work	22,327	6,978
	<u>\$ 32,904</u>	<u>\$ 33,879</u>

#### Note 17 - Private Campaign Contributions

Private campaign contributions consist of both unrestricted and donor restricted contributions and pledges. Donor restricted contributions and pledges are to be used for specific purposes and/or will be paid over a period of time. Private campaign contribution revenue for the years ended December 31 consisted of:

	(In Thousands)	
	2016	2015
Unrestricted contributions	\$ 8,328	\$ 5,715
Temporarily restricted contributions:		
Time restricted	1,937	2,143
Purpose restricted	2,070	2,346
Total temporarily restricted	4,007	4,489
Permanently restricted contributions	4	3
	<u>\$ 12,339</u>	<u>\$ 10,207</u>

## **PATH AND SUBSIDIARIES**

### **Notes to Consolidated Financial Statements For the Years Ended December 31, 2016 and 2015**

---

#### **Note 18 - Derivative Instruments and Hedging Activities**

Beginning in 2016, the Organization's risk management strategies include the use of foreign exchange (FX) derivative contracts. The goal of these strategies is to mitigate both market and economic risk so that movements in currency fluctuations do not adversely affect the value of the Organization or its ability to deliver on its contractual obligations and overall mission. The net fair value of the FX derivative contracts, reported at market value, is included in prepaid expenses and other on the consolidated statements of financial position.

At December 31, 2016 the Organization had in place foreign currency contracts for purchases of U.S. dollars (USD) with notional amounts totaling \$67,297,150 and sales of USD for foreign currencies with notional amounts totaling \$32,839,360. At December 31, 2016 the fair values of FX contracts held recognized in the consolidated statement of financial position are an asset of \$439,000. The currencies being hedged are Euros and Great Britain Pounds.